104 related articles for article (PubMed ID: 17582311)
1. [Irinotecan and liver dysfunctions].
Sablin MP; Le Tourneau C; Faivre S; Raymond E
Therapie; 2007; 62(2):111-5. PubMed ID: 17582311
[TBL] [Abstract][Full Text] [Related]
2. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
Mehra R; Murren J; Chung G; Smith B; Psyrri A
Clin Colorectal Cancer; 2005 May; 5(1):61-4. PubMed ID: 15929808
[TBL] [Abstract][Full Text] [Related]
3. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity.
Biason P; Masier S; Toffoli G
J Chemother; 2008 Apr; 20(2):158-65. PubMed ID: 18467239
[TBL] [Abstract][Full Text] [Related]
4. UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy.
Ando Y; Fujita K; Sasaki Y; Hasegawa Y
Curr Opin Mol Ther; 2007 Jun; 9(3):258-62. PubMed ID: 17608024
[TBL] [Abstract][Full Text] [Related]
5. UGT1A1 polymorphism predicts irinotecan toxicity: evolving proof.
Mani S
AAPS PharmSci; 2001; 3(3):3. PubMed ID: 11783425
[No Abstract] [Full Text] [Related]
6. Pharmacogenetics of irinotecan disposition and toxicity: a review.
Fujita K; Sparreboom A
Curr Clin Pharmacol; 2010 Aug; 5(3):209-17. PubMed ID: 20406168
[TBL] [Abstract][Full Text] [Related]
7. UGT1A1 genotyping in patients undergoing treatment with irinotecan.
Innocenti F
Clin Adv Hematol Oncol; 2005 Nov; 3(11):843-4. PubMed ID: 16491625
[No Abstract] [Full Text] [Related]
8. Irinotecan pharmacogenomics.
Marsh S; Hoskins JM
Pharmacogenomics; 2010 Jul; 11(7):1003-10. PubMed ID: 20602618
[TBL] [Abstract][Full Text] [Related]
9. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan.
Stewart CF; Panetta JC; O'Shaughnessy MA; Throm SL; Fraga CH; Owens T; Liu T; Billups C; Rodriguez-Galindo C; Gajjar A; Furman WL; McGregor LM
J Clin Oncol; 2007 Jun; 25(18):2594-600. PubMed ID: 17577039
[TBL] [Abstract][Full Text] [Related]
10. Insights, challenges, and future directions in irinogenetics.
Kim TW; Innocenti F
Ther Drug Monit; 2007 Jun; 29(3):265-70. PubMed ID: 17529881
[TBL] [Abstract][Full Text] [Related]
11. Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan.
Takano M; Kato M; Yoshikawa T; Goto T; Furuya K; Kikuchi Y
Int J Clin Oncol; 2010 Apr; 15(2):224-5. PubMed ID: 20179984
[No Abstract] [Full Text] [Related]
12. Pharmacogenetics of irinotecan: a promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan.
Ando M; Hasegawa Y; Ando Y
Invest New Drugs; 2005 Dec; 23(6):539-45. PubMed ID: 16267624
[TBL] [Abstract][Full Text] [Related]
13. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
Fakih MG; Ross ME; Starostik P
Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic approach for cancer treatment-tailored medicine in practice.
Hasegawa Y; Ando Y; Ando M; Hashimoto N; Imaizumi K; Shimokata K
Ann N Y Acad Sci; 2006 Nov; 1086():223-32. PubMed ID: 17185519
[TBL] [Abstract][Full Text] [Related]
15. UGT1A and irinotecan toxicity: keeping it in the family.
Hoskins JM; McLeod HL
J Clin Oncol; 2009 May; 27(15):2419-21. PubMed ID: 19364959
[No Abstract] [Full Text] [Related]
16. Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy.
Akiyama Y; Fujita K; Nagashima F; Yamamoto W; Endo H; Sunakawa Y; Yamashita K; Ishida H; Mizuno K; Araki K; Ichikawa W; Miya T; Narabayashi M; Kawara K; Sugiyama M; Hirose T; Ando Y; Sasaki Y
Ann Oncol; 2008 Dec; 19(12):2089-90. PubMed ID: 18953066
[No Abstract] [Full Text] [Related]
17. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
Innocenti F; Ratain MJ
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):52-5. PubMed ID: 12800608
[TBL] [Abstract][Full Text] [Related]
18. Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Soepenberg O; Dumez H; Verweij J; de Jong FA; de Jonge MJ; Thomas J; Eskens FA; van Schaik RH; Selleslach J; Ter Steeg J; Lefebvre P; Assadourian S; Sanderink GJ; Sparreboom A; van Oosterom AT
Clin Cancer Res; 2005 Feb; 11(4):1504-11. PubMed ID: 15746053
[TBL] [Abstract][Full Text] [Related]
19. Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer.
Fukuda M; Okumura M; Iwakiri T; Arimori K; Honda T; Kobayashi K; Senju H; Takemoto S; Ikeda T; Yamaguchi H; Nakatomi K; Matsuo N; Mukae H; Ashizawa K
Thorac Cancer; 2018 Jan; 9(1):51-58. PubMed ID: 29052349
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis.
Hu ZY; Yu Q; Zhao YS
Eur J Cancer; 2010 Jul; 46(10):1856-65. PubMed ID: 20335017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
